Affiliation:
1. Miller School of Medicine, University of Miami, Miami, Florida, USA; Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA
Abstract
Abstract
Learning Objectives
After completing this course, the reader will be able to: Discuss the value of adjuvant chemotherapy in early breast cancer.Critically assess the use of anthracyclines as part of adjuvant chemotherapy.Describe the delivery of anthracyclines regarding dose, dose intensity, and dose density.Evaluate the use of trastuzumab in the adjuvant setting.
Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com
Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets, including situations where use of dose-dense and/or dose-intense protocols may provide additional benefits and where combinations including taxanes and/or trastuzumab may provide increased efficacy. Epirubicin also has a distinct safety profile compared to doxorubicin with regard to cardiotoxicity. In order to optimize treatment benefits and safety concerns for node-positive, node-negative and HER-2–positive patients as well as patients receiving neoadjuvant therapy and elderly patients it is worthwhile to consider the potential benefits of epirubicin.
Publisher
Oxford University Press (OUP)
Reference59 articles.
1. Combination chemotherapy as an adjuvant treatment in operable breast cancer;Bonadonna;N Engl J Med,1976
2. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23;Fisher;J Clin Oncol,2001
3. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: a Southeastern Cancer Study Group study;Carpenter;Proc Am Soc Clin Oncol,1994
4. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group;Martin;Ann Oncol,2003
5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTCG);Lancet,2005
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献